Literature DB >> 671662

Interaction between quinidine and digoxin.

E B Leahey, J A Reiffel, R E Drusin, R H Heissenbuttel, W P Lovejoy, J T Bigger.   

Abstract

The serum digoxin concentration increased in 25 of 27 study patients (93%), and the mean serum digoxin concentration rose from 1.4 ng/ml to 3.2 ng/ml during quinidine therapy. Anorexia, nausea, or vomiting developed in 16 patients (59%) but disappeared in all ten patients for whom the digoxin dose alone was reduced, suggesting that digoxin excess caused these symptoms. Ventricular premature depolarizations developed in three patients after starting quinidine therapy; ventricular tachycardia developed in one patient, and another died suddenly. When starting quinidine therapy in patients who are taking digoxin, the clinical course, ECG, and serum digoxin level should be followed closely.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 671662

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  29 in total

1.  P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate?

Authors:  Praveen V Balimane; Anthony Marino; Saeho Chong
Journal:  AAPS J       Date:  2008-12-11       Impact factor: 4.009

Review 2.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 3.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

Review 4.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 5.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

6.  The relation of quinidine-induced elevation of serum digoxin concentration to the conversion of atrial fibrillation-flutter: a pilot study.

Authors:  S Shah; H S Friedman
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

Review 7.  Pharmacokinetic drug interactions between digoxin and antiarrhythmic agents and calcium channel blocking agents: an appraisal of study methodology.

Authors:  E M Antman; J M Arnold; P L Friedman; T W Smith
Journal:  Cardiovasc Drugs Ther       Date:  1987-08       Impact factor: 3.727

Review 8.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

9.  Effect of coadministration of verapamil and quinidine on serum digoxin concentration.

Authors:  W Doering
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 10.  Assessing cardiovascular drug safety for clinical decision-making.

Authors:  Raymond L Woosley; Klaus Romero
Journal:  Nat Rev Cardiol       Date:  2013-04-16       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.